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Comparison of MEK/ERK pathway inhibitors on the upregulation of 
vascular G protein coupled receptors in rat cerebral arteries 
 
Hardip Sandhu a, Saema Ansar a, Lars Edvinsson a,b 
 
a
 Department of Clinical Experimental Research, Glostrup Research Institute, Glostrup University 
Hospital, Denmark 
b
 Division of Experimental Vascular Research, Institute of Clinical Sciences in Lund, University 
Hospital of Lund, Lund, Sweden 
 
Abstract 
Organ culture is an in vitro method for investigating cellular mechanisms involved in upregulation 
vasocontractile G-protein coupled receptors (GPCR). We hypothesize that mitogen activated pro-
tein kinase kinase (MEK) and/or extracellular signal-regulated kinase (ERK) specific inhibitors will 
attenuate the GPCR expression following organ culture. 
Rat cerebral arteries were incubated for 48 h in the presence of MEK/ERK specific inhibitors 
U0126, PD98059, SL327, or AG126 for different time periods. Contractile responses by activation 
of endothelin receptor type A and type B, serotonin receptor 5-HT1B, thromboxane A2 receptor, 
and angiotensin II receptor type 1 and type 2 were investigated. Results were verified by measure-
ment of mRNA with real time PCR and by protein immunohistochemistry. 
Organ culture induced transcriptional upregulation of endothelin ETB receptor and of serotonin 5-
HT1B receptor on translational level and increased respective contractions. The thromboxane A2 
receptor mediated contraction curves was left-wards shifted by organ culture. Organ culture was 
associated with elevated pERK1/2 in the vascular smooth muscle cells: the MEK1/2 inhibitor 
U0126 attenuated the endothelin ETB receptor mediated contraction at post-translational level or by 
changing the receptor affinities. The serotonin 5-HT1B receptor and thromboxane A2 receptor me-
Manuscript
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diated contractions were abolished by U0126. Administration of U0126 6 h after start of incubation 
blocked the receptor upregulation.
 
In conclusion, MEK specific inhibitor U0126 is a potent inhibitor of GPCR alteration seen during 
organ culture. Given the ability to inhibit GPCR alteration at the clinically relevant time-point 6 h 
post incubation makes it an attractive therapeutic agent for in vivo studies.  
 
Keywords: Organ culture; cerebral arteries; vascular smooth muscle cells; GPCR upregulation; 
MEK/ERK pathway; U0126  
 
1 Introduction  
Cerebral ischemia and stroke are the third leading causes of death worldwide and leading causes of 
long-term disability (Rosamond et al., 2008a). The most common type is thromoembolic stroke 
which accounts for 87 % of all stroke incidents; the remaining incidents are caused by intracerebral 
and subarachnoid haemorrhages (SAH) (Rosamond et al., 2007). Substantial efforts have been 
made to understand the intracellular mechanisms involved in ischemia induced cerebral damage, 
with focus primarily on cerebral neurons (neuroprotection), and to develop drugs that protect the 
brain from damage once a stroke has occurred. Despite intense investigation for over three decades, 
few therapies have proven effective in the clinic (Elting et al., 2002;O'Collins et al., 2006). Experi-
mental and clinical studies have shown increased levels of the locally formed vasoconstrictor endo-
thelin-1, angiotensin II, 5-hydroxytryptamine, and thromboxane in cerebral ischemia (Lincoln et al., 
1990;Loesch and Burnstock, 1988;Loesch and Burnstock, 2002);  all the substances mediate vaso-
constriction via specific vascular GPCR (Boess and Martin, 1994;Dudley et al., 1991;Murphy et al., 
1991;Pucell et al., 1991;Sakamoto et al., 1993;Sasaki et al., 1991;Shenker et al., 1991;Tsutsumi et 
al., 1991).  
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We have demonstrated that cerebral ischemia is associated with enhanced expression of vasocon-
strictor GPCRs in the smooth muscle cells of brain arteries, both in the major arteries belonging to 
the circle of Willis and in intracerebral microvessels, but not in brain neurons or glial cells (Ansar et 
al., 2007;Beg et al., 2006;Vikman and Edvinsson, 2006). There is a rapid transcription/translation 
upregulation of contractile endothelin ETA and ETB receptors, angiotensin AT1 and AT2 receptors, 
and serotonin 5-HT1B receptors in the vascular smooth muscle cells after SAH or focal ischemia 
and reperfusion (Hansen-Schwartz et al., 2003a;Hansen-Schwartz et al., 2003b;Stenman et al., 
2002;Stenman and Edvinsson, 2004). Furthermore, the mitogen-activated protein kinase (MAPK) 
signalling pathways are involved in the process of cerebrovascular receptor upregulation (Ansar and 
Edvinsson, 2008;Beg et al., 2006;Henriksson et al., 2007;Maddahi and Edvinsson, 2008). In an ini-
tial study, the MEK1/2 specific inhibitor U0126 reduced the activity of ERK1/2 and blunted the 
increase in vasoconstrictive receptor upregulation, reduced the cerebral infarct volume and im-
proved neurological score after experimental focal ischemic stroke in rodents (Henriksson et al., 
2007;Namura et al., 2001;Maddahi and Edvinsson, 2008).     
 
We have found that organ culture of cerebral arteries is an in vitro method to induce changes in 
GPCR expression in a pattern which resembles that seen in cerebrovascular disease in vivo (Hoel et 
al., 2001a;Rosamond et al., 2008b). The organ culture model allows for detailed studies of the un-
derlying intracellular mechanisms responsible for the upregulation of GPCR in cerebral arteries. We 
hypothesise that MEK/ERK pathway specific inhibitors will prevent the upregulation of contractile 
cerebrovascular GPCRs in smooth muscle cells. The aim of this study was to evaluate the effect of 
available MEK1/2 specific inhibitors U0126, PD98059, and SL327, and the ERK1/2 specific inhibi-
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tor AG126 on vascular GPCR upregulation, to compare their efficacy, and to unravel their treatment 
time window during which each inhibitor effectively prevents GPCR upregulation.  
 
2 Materials and Methods  
2.1 Removal of cerebral vessels and organ culture  
Male Sprague-Dawley rats (n=98; 350-400 g) (Taconic, Denmark) were anaesthetized with CO2 
and decapitated. The brains were removed and immediately chilled in ice-cold bicarbonate buffer 
solution (for composition see below). The right and left middle cerebral artery were removed and 
dissected free. 
 
Middle cerebral artery segments (1 mm long), rings with intact endothelium, were studied immedi-
ately (fresh, 0 h organ culture) or incubated for 48 h at 37 °C in humidified 5 % CO2 and 95 % air 
in serum free Dulbecco’s modified Eagle’s medium (DMEM: 1 mg/ml glucose, 4mM L-glutamine, 
0.11 mg/ml sodium pyruvate) supplemented with an antibiotics mix (10.000 units/ml of penicillin, 
10 mg/ml of streptomycin, and 25 ng/ml of amphotericin B). Thereafter vessels were either 
mounted in myographs for in vitro pharmacology or snap-frozen with dry ice and kept at -80 °C for 
real time PCR or protein immunohistochemistry. When using MEK/ERK1/2 inhibitors, they were 
added to the DMEM medium at 0 h, 6 h, 12 h or 24 h after the initiation of the incubation (Figure 1) 
(U0126: 0.1 µM, 1 µM or 10 µM; PD98059: 0.1 µM, 1 µM, 10 µM, or 30 µM; SL327: 0.1 µM, 1 
µM, 10 µM, 100 µM, or 300 µM; AG126: 0.1 µM, 1 µM or 10 µM). The inhibitors were dissolved 
in dimethyl sulfoxide. Dimethyl sulfoxide added alone was used as vehicle (placebo, control).  
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2.2 Drugs 
DMEM and the antibiotics mix were from Invitrogen (USA). 1-Bromo-3-chloropropane, dimethyl 
sulfoxide, AG126, U0126, PD98059, carbachol, 5-hydroxytryptamin, 5-carboxamidotryptamine, 
PD123319, and U46619 were obtained from Sigma-Aldrich (USA). SL327 was from Biaffin GmbH 
& Co KG (Germany). Endothelin-1, Sarafotoxin 6c, and Angiotensin II were from NeoMPS S.A. 
(France).  
 
2.3 In vitro pharmacology 
A sensitive myograph was used for recording the isometric tension in isolated vessel segments 
(Hogestatt et al., 1983;Mulvany and Halpern, 1977). The vessel segments were threaded on two 40 
µm-diameter stainless steel wires and mounted on a Mulvany-Halpern Myograph (Danish Myo 
Technology A/S, Denmark). One of the wires were connected to a force displacement transducer 
attached to an analog-digital converter unit (PowerLab from ADInstruments, New Zealand), while 
the other wire was attached to a movable displacement device allowing fine adjustments of vascular 
tension by varying the distance between the two wires. The measurements were recorded on a com-
puter using the software Chart 6 (ADInstruments, New Zealand).  
 
The segments were immersed in a temperature-controlled (37 °C) buffer solution (composition in 
mM/ml; NaCl = 119, NaHCO3 = 15, KCl = 4.6, MgCl2 = 1.2, NaH2PO4 = 1.2, CaCl2 = 1.5, and 
glucose = 5.5). The buffer was continuously gassed with 5 % CO2 in O2 resulting in a physiologi-
cal pH at 7.4. The vessels were given an initial pre-tension of 2 mN/mm and adjusted to this tension 
for 1 hour. The contractile capacity was determined by exposure to a 30 mM potassium buffer solu-
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tion with the same composition as the bicarbonate buffer solution except that NaCl is exchanged for 
KCl. The threshold for minimum 30 mM potassium contraction response was set to 0.8 mN.  
 
Carbachol mediated dilation after 5-hydroxytryptamine mediated contraction is used as measure-
ment of endothelium functionality. Carbachol mediates an endothelium dependent dilation of ves-
sels. 5-hydroxytryptamine mediates a strong smooth muscle cell dependent contraction. This con-
traction is used as a reference for maximum contraction of the vessel when endothelium functional-
ity is measured. Middle cerebral artery segments were pre-contracted with 3 µM 5-
hydroxytryptamine and subsequently exposed to 10 µM carbachol. A strong dilation by carbachol 
indicates intact and/or functional endothelium, whereas a weak or absent dilation indicates damaged 
or unfunctional endothelium (i.e. due to mechanical damage of the endothelium during mounting on 
wires). Threshold for maximal endothelium presence/function was set to 30 % carbachol induced 
dilatation, and only vessels showing this response or less were included, as we are interested in ob-
serving the GPCR response in smooth muscle cells only. Concentration-response curves were then 
obtained by cumulative application of the agonists endothelin-1 (1 10-14 M to 10-7 M), sarafotoxin 
6c (10-14 M to 10-7 M), 5-carboxamidotryptamine (10-12 M to 3*10-5 M), angiotensin II (10-12 
M to 3*10-6 M), and U46619 (10-12 M to 3*10-6 M). The angiotensin AT2 receptor antagonist 
PD123319 was added at a concentration of 30 µM 30 min prior to the angiotensin II concentration-
response curve when the angiotensin AT1 receptor response was studied. 
 
2.4 Molecular Biology  
Isolated middle cerebral artery was snap-frozen with dry ice in green-cap tubes containing Lysing 
Matrix D provided in the FastRNA Pro Green Kit (Q Biogene, USA) after removal. Total cellular 
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RNA was extracted with use of the FastRNA Pro Green Kit following the supplier’s instructions. 
The vessels were homogenized in 1 ml of RNApro Solution by using a FastPrep FP120 instrument 
(Q Biogene, USA). The samples were centrifuged for 15 min at 4 °C at 12,500 g, and the liquid 
phase was transferred to 300 µl of 1-bromo-3-chloropropane. After centrifugation for 15 min at 4 
°C at 12,500 g the upper phase was transferred to 500 µl of 100 % ethanol and stored at minus 20 
°C over-night. Next day the samples were centrifuged for 20 min at 4 °C at 15,000 g. The super-
natant was removed. The pellet was washed with 500 µl 75 % ethanol, air dried and re-dissolved 
with RNase free water. Total RNA quantity and purity was determined using a GeneQuant II spec-
trophotometer (Pharmacia Biotech, UK) measuring the absorbance at 260 nm and 280 nm. Demon-
stration of a high RNA quality, the A260/A280 ratio value was around 1.8 – 2.0.  
 
Reverse transcription of total RNA to cDNA was performed with the TaqMan Reverse Transcrip-
tion Reagents (Applied Biosystems, USA) in a GeneAmp PCR System 2400 (Perkin-Elmer, USA). 
First-strand cDNA was synthesized from 250 ng total RNA in a 30 µl reaction volume where ran-
dom hexamers were used as primers. The PCR reaction was performed with the following setup: 42 
°C for 90 min followed by 72 °C for 10 min. The cDNA was diluted with 20 µl of RNase free water 
when used in the real time PCR reaction. 
 
Real time PCR was performed in a 7500 Fast Real Time PCR sequence detection system (Applied 
Biosystems, USA) with the SYBR Green PCR Master Mix (Applied Biosystems, USA) with 1 µl 
cDNA synthesized above as template in a 25 µl reaction volume. A none-template control was in-
cluded in all experiments. The 7500 Fast Real Time PCR sequence detection software SDS version 
1.4 (Applied Biosystems, USA) monitored the amplification of DNA in real time by optics and im-
aging system via the binding of a fluorescent dye to double-stranded DNA.  
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Elongation factor-1 (EF-1) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA were 
used as reference housekeeping genes (Stenman et al., 2002;Stenman and Edvinsson, 2004). Spe-
cific primers for the rat endothelin ETA ands ETB receptors, serotonin 5-HT1B receptor, throm-
boxane A2 receptor, EF-1, and GAPDH were designed (Table 1). One µl 10 mM primer was added 
to the 25 µl real time PCR reaction. The real time PCR was performed with the following profile: 
50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles with 95°C for 15 seconds and 
60 °C for 1 minute. 
 
 
2.5 Immunohistochemistry 
The middle cerebral artery was dissected out and then placed into Tissue TEK (Sakura Finetek 
Europe B.V., Netherlands) and frozen. Segments were sectioned into 10-µm-thick slices and 
mounted on SuperFrost Plus slides (Menzel GMBH & COKG, Germany). 
The primary antibodies used were sheep anti-rat endothelin ETB receptor
 (ab50658, Abcam, UK), 
diluted 1:200; rabbit anti-rat serotonin 5-HT1B receptor (ab13896, Abcam, UK), diluted 1:500; 
rabbit anti-rat thromboxane A2 receptor (ab65150, Abcam, UK), diluted 1:200; rabbit anti-rat 
pERK1/2 (4370, Cell Signalling, USA), diluted 1:1000; and mouse anti-rat β-actin (ab11003, Ab-
cam, UK), diluted 1:500. The endothelin ETB receptor, serotonin 5-HT1B receptor, and pERK1/2 
dilutions were done in phosphate buffered saline with 2 % donkey serum (017-000-121, Jackson 
ImmunoResearch laboratories, Inc., USA), while the thromboxane A2 receptor dilution was done in 
phosphate buffered saline with 2 % goat and donkey serum (005-000-121 and 017-000-121 Jackson 
ImmunoResearch laboratories, Inc., USA). 
 
 
 9 
The secondary antibodies used were donkey anti-sheep DL488 conjugated (STAR88D488, AbD 
Serotec, USA), diluted 1:200; donkey anti-rabbit DL488 conjugated (711-485-152, Jackson Immu-
noResearch, USA), diluted 1:200; goat anti-rabbit FITC conjugated (ab6717, Abcam, UK), diluted 
1:200; donkey anti-rabbit DL459 conjugated (711-505-152, Jackson ImmunoResearch, USA), di-
luted 1:200; and donkey anti-mouse DL549 conjugated (715-505-150, Jackson ImmunoResearch, 
USA), diluted 1:200. As control, only secondary antibodies were used. The antibodies were detected 
at the appropriate wavelength on a confocal microscopy (Nikon, C1plus, Nikon Instruments Inc., 
USA).  
 
2.6 Calculation and statistical analyses  
Data are expressed as mean values ± standard error of the mean (s.e.m.), and n refers to the number 
of rats. Statistical analyses were performed with one way ANOVA (non-parametric Kruskal-Walis 
test) with Bonferroni’s test (groups compared: organ culture of vehicle vs. fresh or organ culture 
with 10 µM U0126 at specific time points), where P< 0.05 was considered statistically significant 
(P< 0.05=*, P< 0.01=**, P< 0.001=***, and not significant = n.s.). 
 
2.6.1 In vitro Pharmacology 
 
Contractile responses in each segment are expressed as percentage of the 30 mM K+ induced con-
traction. Emax value represents the maximum contractile response elicited by an agonist and the 
pEC50 the negative logarithm of the drug concentration that elicited half the maximum response. For 
biphasic responses, Emax(1) and pEC50(1) describes the high affinity phase and Emax(2) and 
pEC50(2)) describes the low affinity phase.   
 
 10 
2.6.2 Real-time PCR 
 
Data were analysed with the comparative cycle threshold (CT) method (Hansen-Schwartz et al., 
2002). The CT values of EF-1 or GAPDH mRNA were used as a reference to quantify the relative 
amount of endothelin ETA and ETB receptor, serotonin 5-HT1B receptor, and thromboxane A2 
receptor
 
mRNA. The relative amount of mRNA was calculated with the CT values of endothelin 
ETA and ETB receptor, serotonin 5-HT1B receptor, and thromboxane A2 receptor and receptor 
mRNA in relation to the CT values of EF-1 or GAPDH mRNA in the sample by the formula 
X0/R0=2CtR-CtX, where X0 is the original amount of target mRNA, R0 is the original amount of EF-1 or 
GAPDH mRNA, CtR is the CT value for EF-1 or GAPDH, and CTX is the CT value for the target. 
Data with EF-1 as the reference gene is shown in results section.
 
 
2.6.3 Immunohistochemistry 
 
Images were analysed by Nikon EZ-C1 software version 3.70. Fluorescence intensity was measured 
on the whole smooth muscle cell area in 3 sections; the mean of this was used. β-actin staining was 
used as reference of smooth muscle cell localization. Analysis was done by having the red 488 nm 
channel (β-actin conjugated) overlay; however, only green 549 nm channel (receptor conjugated) 
image is given for visual simplicity. Mean fluorescence intensity of the green channel image was 
compared in the different groups, where fresh group was used as a reference. 
 
3 Results  
3.1 Organ culture and receptor upregulation 
Middle cerebral arteries were incubated for 48 h with the MEK/ERK inhibitor or their solvent di-
methyl sulfoxide (in the dose of 2.5 µl/ml of DMEM dimethyl sulfoxide had no effect; data not 
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shown). There was no significant difference of K+-induced contractions between fresh and vehicle 
incubated vessels (30 mM K+ values as mean ± s.e.m.: fresh = 2.58 mN ± 0.28; 48 h organ culture 
dimethyl sulfoxide vehicle = 2.83 mN ± 0.26). 
 
 
3.1.1 Endothelin receptors 
 
Sarafotoxin 6c did not induce any contraction of fresh cerebral artery segments, while endothelin-1 
produced a strong concentration dependent contraction (Emax in % of K+ = 139 ± 14 mN). After 48 
h of organ culture, sarafotoxin 6c resulted in a strong concentration-dependent contraction (Figure 
2C, Table 2). The response to endothelin-1 showed no change in maximum contraction or pEC50 
(Figure 2B, Table 2). As demonstrated previously the sarafotoxin 6c effect was mediated by 
upregulated endothelin ETB receptors (Henriksson et al., 2003). Administration of endothelin-1 – 
following a sarafotoxin 6c mediated contraction curve - resulted in activation of the endothelin ETA 
receptors only due to desensitisation of endothelin ETB receptors (Adner et al., 1994). The upregu-
lation of the endothelin ETB receptors was confirmed by real time PCR of receptor mRNA levels 
(Figure 3A) and receptor protein immunohistochemistry (Figure 3B). Endothelin ETA receptor 
mRNA or protein was not changed after 48 h of vehicle compared to fresh vessels (data not shown). 
 
 
3.1.2 5-HT receptors 
5-carboxamidotryptamine was used as an agonist because it activates both serotonin 5-HT1B recep-
tor and serotonin 5-HT2A receptors (Hoel et al., 2001b). Careful study of rat cerebral arteries have 
shown that they mainly contain the 5-HT2A subtype of receptors, however, organ culture resulted 
in upregulation of the serotonin 5-HT1B receptor subtype (Hansen-Schwartz et al., 2002;Hoel et al., 
2001b). The rat middle cerebral artery 5-carboxamidotryptamine contraction Emax almost doubled 
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from fresh to after 48 h of organ culture (Figure 4A, Table 2). The 5-carboxamidotryptamine medi-
ated contraction of fresh middle cerebral artery results in a sigmoid curve, while the curve of incu-
bated vessels gives a biphasic curve. There was no significant difference in the serotonin 5-HT1B 
receptor mRNA levels (data not shown), but protein immunohistochemistry showed a significant 
rise in the serotonin 5-HT1B receptor level between fresh vessels and vessels with vehicle after 48 h 
of organ culture (Figure 4B). 
 
 
3.1.3 Thromboxane A2 receptors 
The thromboxane A2 receptor agonist U46619 induced strong contraction of fresh middle cerebral 
artery segments as well as vessels incubated for 48 h (Figure 5A, Table 2). There is a slight left-
ward shift from fresh to 48 h incubated middle cerebral artery, but without significance (p>0.05). 
There was a no difference in thromboxane A2 receptor mRNA levels between fresh and 48 h incu-
bated middle cerebral artery (data not shown). Protein immunohistochemistry did not show any 
difference in thromboxane A2 receptor protein level from fresh to 48 h incubated middle cerebral 
artery (Figure 5B). 
 
3.1.4 Angiotensin AT receptors 
We have before observed a week contraction by angiotensin II of rat middle cerebral artery in fresh 
vessels and a stronger contraction after cerebral ischemia (Stenman and Edvinsson, 2004). How-
ever, organ culture did not reveal any enhanced contraction to angiotensin II whether or not the an-
giotensin AT2 receptor receptor antagonist PD123319 (30 µM) was present (data not shown). 
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3.2 MEK / ERK inhibitors 
Available MEK/ERK1/2 inhibitors were tested primarily on the endothelin ETB receptor upregula-
tion because this response to organ culture was strong and reproducible. K+-induced contractions 
did not differ significantly in vehicle vessels compared to vessels incubated with MEK/ERK inhibi-
tors (30 mM K+ values in mN as mean ± s.e.m.: 48 h organ culture vehicle = 2.83 ± 0.26; 48 h or-
gan culture 10 µM U0126 = 2.20 ± 0.23; 48 h organ culture 10 µM PD98059 = 3.60 ± 0.38; 48 h 
organ culture 10 µM SL327 = 2.35 ± 0.32), except for AG126 (30 mM K+ values in mN as mean ± 
s.e.m.: 48 h organ culture 1 µM AG126 = 1.72 ± 0.42). 
 
3.2.1 U0126 
The direct effect of U0126 was tested on fresh middle cerebral artery and on segments organ cul-
tured for 48 h. U0126 in the concentration interval 10-14 M to 10-5 M did not alter the basal vascu-
lar contractile tone. In addition, 10 µM U0126 had no dilatory effect on pre-contracted vessels, and 
did not alter the 30 mM K+ max response (data not shown; n=6). 
 
The second set of experiments was performed to evaluate the effects of U0126 on endothelin ETB 
receptor activation and expression. Middle cerebral artery co-incubated with 10 µM U0126 for 48 h 
showed significantly reduced endothelin ETB receptor mediated maximum contraction compared to 
control (Figure 2C, Table 2). There was a time-dependent rightward shift of the concentration-
contraction curve to endothelin-1 with prior exposure to sarafotoxin 6c after incubation with U0126 
(Figure 2A, Table 2). The concentration of U0126 was kept at 10 µM because previous study in our 
group has shown that this concentration is optimal (Henriksson et al., 2004); lower doses (0.1 – 1 
µM) were without significant effect (tested in the present study; data not shown). 
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3.2.2 PD98059 
The MEK1/2 specific inhibitor PD98059 (Alessi et al., 1995;Dudley et al., 1995) was tested at dif-
ferent concentrations; 0.1 µM, 1 µM, 10 µM, and 30 µM. The result was the same for all these con-
centrations. PD98059 did not inhibit the upregulation of the endothelin ETB receptors after 48 h of 
organ culture of rat middle cerebral artery. PD98059 in concentrations above 30 µM altered the 
contractile tone of the vessels, and hence the effect on endothelin ETB receptor upregulation of 
doses above 30 µM was not tested (data not shown). 
 
3.2.3 SL327 
The MEK1/2 specific inhibitor SL327 (Favata et al., 1998b) was tested at different concentrations 
0.1 µM, 1 µM, 10 µM, 100 µM, and 300 µM. SL327 did not inhibit the endothelin ETB receptor 
dependent contractions after 48 h of middle cerebral artery organ culture in the doses studied.  
 
3.2.4 AG126 
The ERK1/2 specific inhibitor AG126 (Novogrodsky et al., 1994) significantly reduced both the 
endothelin ETA and ETB receptor mediated contractions in middle cerebral artery after 48 h of or-
gan culture. The 30 mM K+ contraction was however also reduced by 1 µM AG126 (p<0.05) when 
compared to vehicle incubation (30 mM K+ values in mN as mean ± s.e.m.: 48 h organ culture ve-
hicle = 2.83 ± 0.26 and 48 h organ culture 1 µM AG126 = 1.72 ± 0.42). Emax values of both the 
endothelin ETA and ETB receptor were reduced and pEC50 significantly shifted to the right after 
administration of AG126 at the start of organ culture (endothelin ETA receptor mediated contrac-
tion: 48 h organ culture with vehicle Emax = 132 ± 4 % and pEC50 = 12.1 ± 0.2 and 48 h organ 
culture with 1 µM AG126 Emax = 82 ± 9.1 % and pEC50 = 10.6 ± 0.3; endothelin ETB receptor 
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mediated contraction: 48 h organ culture with vehicle Emax = 121 ± 6 % and pEC50 = 11.7 ± 1.0, 
and 48 h organ culture with 1 µM AG126 Emax = 79 ± 11 % and pEC50 = 10.5 ± 0.2). However, 
AG126 did not inhibit the receptor alteration when it was added to the organ culture at the other 
time points (6, 12, or 24 h after start of organ culture), or in lower or higher doses (data not shown). 
 
3.3 Expression of pERK1/2 
Organ culture resulted in a strong expression in the activated (phosphorylated) form of ERK1/2 
(pERK1/2) in the middle cerebral artery smooth muscle cells; pERK1/2 co-localized with actin. 
Total ERK1/2 was not altered (data not shown). To verify whether pERK1/2 was reduced by the 
specific MEK/ERK inhibitors we performed immunohistochemistry of vessels incubated for 48 h 
with vehicle, 10 µM U0126, 10 µM PD98059, 10 µM SL327, and 1 µM AG126. These experiments 
revealed that the increased pERK1/2 activity by organ culture was attenuated by U0126 and 
AG126, whereas PD98059 and SL327 failed to do so (Figure 6). In addition, U0126 added 6 h after 
the start of the organ culture also showed significant reduction in pERK1/2. 
 
3.4 Time study of MEK inhibition 
In order to examine in more detail the inhibitory potential of the two MEK/ERK1/2 inhibitors 
U0126 and AG126 studies were performed adding the blockers to the medium at different time 
points after initiation of the organ culture. AG126 failed to inhibit the endothelin ETB receptor 
upregulation when it was given 6 h after initiation of the organ culture; thus further study of this 
blocker was discontinued. Vessel segments were incubated with 10 µM U0126 (start of U0126 ad-
ministration 6 h, 12 h, or 24 h after initiation of organ culture, see Figure 1) and receptor upregula-
tion was studied of  the by using myographs, real time PCR and immunohistochemistry.  
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3.4.1 Endothelin ETA receptor and endothelin ETB receptor receptors 
Organ culture for 48 h resulted in a strong sarafotoxin 6c induced contraction, associated with ele-
vated expression of endothelin ETB receptor mRNA and protein, localised to the cytoplasm of the 
smooth muscle cell (Figures 3A+B). The upregulated endothelin ETB receptor mediated contrac-
tion is time dependently reduced by 10 µM U0126. The Emax of sarafotoxin 6c is 121 ± 6 % for 
vehicle vessels relative to contraction elicited by 30 mM potassium. The Emax for the 0 h, 6 h, 12 
h, and 24 h incubation with 10 µM U0126 is reduced to 78 ± 8 %, 10 ± 4 %, 5 ± 1 %, and 70 ± 9 %, 
respectively (Figure 2C, Table 2). Addition of 10 µM U0126 after 6 h or 12 h after initiation of or-
gan culture gives the strongest inhibition by U0126. 
 
There was no significant change in the maximum contractile responses to endothelin-1 when 10 µM 
U0126 was added to the organ culture in the presence of sarafotoxin 6c desensitising, resulting in 
only endothelin ETA receptor activation (Figure 2A). However, there was a shift of the endothelin-
1 responses in the lower half of the endothelin-1 concentration-response curve when both ET recep-
tors are activated at the same time (Figure 2A). Organ culture for 48 h shifts the endothelin-1 
pEC50 value for endothelin ETA receptor and endothelin ETB receptor mediated contraction to the 
left from fresh vessels (pEC50 = 9.3 ± 0.1) to incubated vehicle vessels (pEC50 = 10.8 ± 0.2). Ad-
dition of 10 µM U0126 after 6 h or 12 h of organ culture initiation gives the most dominant right-
ward shift by U0126. These are the same time periods for which the endothelin ETB receptor medi-
ated contraction is inhibited strongest by 10 µM U0126. The endothelin ETA receptor mediated 
contraction was not altered by organ culture (Figure 2A, Table 2). U0126 was therefore not admin-
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istered to this curve. There was no significant change in the mRNA levels of endothelin ETA recep-
tors between organ culture for 48 h with vehicle or 10 µM U0126 (data not shown). 
 
3.4.2 Serotonin 5-HT1B receptor  
5-carboxamidotryptamine induced a biphasic concentration-dependent contraction of rat middle 
cerebral artery after 48 h organ culture. U0126 (10 µM) strongly inhibits the serotonin 5-HT1B re-
ceptor
 
mediated contraction by almost 100 % at all three time points (Figure 4A, Table 2). There 
was no change in serotonin 5-HT1B receptor mRNA at the different time points or treatments (data 
not shown). Protein immunohistochemistry revealed a significant reduction of in the protein level 
when 10 µM U0126 was added to the 48 h organ culture (Figure 4B).
 
 
3.4.3 Thromboxane A2 receptor 
The thromboxane A2 receptor agonist U46619 mediated contraction was inhibited strongly by 10 
µM U0126 when added 6 h after initiation of organ culture. All time points of incubation with 10 
µM U0126 (6 h, 12 h and 24 h), also resulted in a right-ward shift of the thromboxane A2 receptor 
mediated contraction (Figure 5A, Table 2). Incubation with 10 µM U0126 for 42 h did not change 
the thromboxane A2 receptor mRNA significantly compared to fresh or 48 h organ culture with 
vehicle (data not shown). Immunohistochemistry showed no difference in the thromboxane A2 re-
ceptor protein level from fresh to organ culture for 48 h. When U0126 was added to the organ cul-
ture there was a significant down-regulation of thromboxane A2 receptor protein level (Figure 5B). 
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4 Discussion  
The present study has demonstrated by functional and molecular studies, that organ culture results 
in upregulation of endothelin ETB receptor, serotonin 5-HT1B receptor, and thromboxane A2 re-
ceptor in rat middle cerebral artery, via enhanced transcription and/or translation in the smooth 
muscle cells. The main aim of this work was to evaluate the effect of available MEK/ERK1/2 in-
hibitors on the upregulation of cerebrovascular smooth muscle cell receptors and the time-
dependency of this effect. We observed that U0126 had a strong antagonistic effect even if it was 
given up to 12 h after initiation of the organ culture procedure. Thus, the upregulation of GPCR’s 
involves the MEK/ERK1/2 pathway, and U0126 attenuates the upregulation of endothelin ETB 
receptor, serotonin 5-HT1B receptor, and thromboxane A2 receptor, and the pERK1/2 activity 
(Favata et al., 1998b). AG126 also showed an inhibitory effect but it was effective only when ad-
ministrated at the initiation of the organ culture. The other MEK/ERK inhibitors tested were inef-
fective in non-toxic doses and this was confirmed by the lack of modification of pERK1/2 in the 
vessel walls. All the MEK/ERK inhibitors studied have earlier been verified to inhibit this pathway 
in cell culture studies (Chen et al., 2009;Moon et al., 2002). The difference between the effects of 
the inhibition in cell culture studies versus organ culture in the present study is probably due to dif-
ferences in their concentration-effect profile in isolated cells versus a whole vessel segment.
 
 
There is a clear association between cerebrovascular receptor upregulation and activation of the 
MAPK pathway after organ culture; the phenotypic change of GPCR’s occurs in the smooth muscle 
cell and does not involve the endothelium (Favata et al., 1998a;Beg et al.,2006;Maddahi et al., 
2009). The organ culture model provides a method which to some extent mimics the receptor 
changes that are seen in vivo (Hansen-Schwartz et al., 2003b;Stenman et al., 2002) and thereby fa-
cilitates the study of intracellular mechanisms involved in more detail. In vivo studies using West-
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ern blot revealed that the MEK/ERK pathway was activated early (within the first hour) while the 
JNK and p38 MAPK’s were only activated at 48 h after cerebral ischemia (Ansar and Edvinsson, 
2008). The present study focused on investigating which of the MAPK inhibitors that most effec-
tively prevented the upregulation of contractile GPCRs and if they would be effective even when 
given after the initiation of the upregulation process. This is particularly important when consider-
ing MEK/ERK inhibition as a potential therapeutic target for prevention of the organ culture in-
duced upregulation of vasoconstrictor receptors and the reduced cerebral blood flow in experimen-
tal cerebral ischemia.  
 
The study revealed that organ culture caused enhanced contractile responses to sarafotoxin 6c and 
in part to endothelin-1, due to upregulation of smooth muscle cell endothelin ETB receptors, as 
verified by real time PCR of mRNA expression, and protein immunohistochemistry and function. 
The contractile response to 5-carboxamidotryptamine was increased, and in parallel an increased 
protein level demonstrated by immunohistochemistry; however there was no change in the sero-
tonin 5-HT1B receptor mRNA. This suggests an upregulation in serotonin 5-HT1B receptors via 
increased translation. Thromboxane A2 receptor mediated contraction was shifted left-ward by or-
gan culture, suggesting upregulation of thromboxane A2 receptor contraction; however, there was 
no change in mRNA or protein immunohistochemistry. There was no change in the angiotensin 
receptor function or expression.
 
 
Four inhibitors were examined in this study, three of them are MEK1/2 specific (U0126, PD98059, 
and SL327), while AG126 is an ERK1/2 specific inhibitor. They have been shown to be neuropro-
tective in vivo or in vitro (Namura et al., 2001;Alessandrini et al., 1999;Wang et al., 2003;Kann et 
al., 2004). Most of the potential pharmacologic agents that have been identified recently do not 
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cross the blood-brain barrier and therefore require intracisternal administration; U0126 and 
PD98059 fall into this category (Atkins et al., 1998;Garrington and Johnson, 1999), however, if the 
dose is increased it may have effects in vivo (Maddahi and Edvinsson, 2008). SL327 and AG126 on 
the other hand are able to cross the blood-brain barrier and are effective in the CNS when adminis-
tered intraperitoneally (Angstwurm et al., 2004;Atkins et al., 1998), this makes them attractive as 
potential therapeutic agents. U0126 is highly selective towards both MEK 1 and MEK 2, suppress-
ing both inactive and active forms of MEK 1 and / or MEK 2 (IC50 = 72 nM for MEK 1 and IC50 = 
58 nM for MEK 2) (Davies et al., 2000;Favata et al., 1998b). PD98059 specifically binds to the 
inactive form of both MEK 1 and MEK 2, thereby preventing MEK 1 and MEK 2 to be phosphory-
lated by cRAF or MEK kinase (IC50 = 2-7 µM for MEK1 and MEK2) (Favata et al., 1998b). 
SL327 selectively inhibits MEK 1 and MEK 2 (IC50 = 0.18 µM for MEK 1 and IC50 = 0.22 µM 
for MEK 2), and thereby inhibits the phosphorylation of ERK 1/2  (Scherle et al., 2000). Further-
more, SL327 also inhibits and delays MEK activation by interfering with MEK activation by Raf 
(Rauh-Adelmann et al., 2008). Tyrphostin AG126 selectively inhibits the phosphorylation of ERK 1 
and ERK 2 (IC50 = 25-50 µM) (Hanisch et al., 2001;Novogrodsky et al., 1994). 
 
We observed that under our experimental conditions only U0126 and AG126 could inhibit the acti-
vated form of ERK1/2 and the receptor upregulation in concentrations that did not have any effect 
on the basal vascular tone. AG126 had only effect when given at the beginning of the organ culture. 
Importantly, U0126 inhibited receptor upregulation also when given 6 h after initiation of organ 
culture procedure; this is a more interesting profile if we consider administration of a drug after 
initiation of cerebral ischemia in vivo. This result correlates with in vivo observations: Maddahi and 
Edvinsson observed that U0126, given 6 h after middle cerebral artery occlusion for 2 h and then 
reperfusion for 48 h depressed of the enhanced expression of pERK1/2 in cerebral vessels and the 
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upregulation of endothelin ETB receptors (Maddahi and Edvinsson, 2008). We found that there is a 
clear time-dependency of the effect of U0126 depending on the time of application after organ cul-
ture initiation, illustrating a potential window for therapy. Treatment with U0126 up to 6 hrs after 
middle cerebral artery occlusion attenuated the elevated endothelin ETB receptor and mediated con-
traction, reduced the protein levels of endothelin ETB, angiotensin AT1, and serotonin 5-HT1B 
receptors,
 
and phosphorylation of ERK 1/2 and Elk-1 (Maddahi and Edvinsson, 2008). Furthermore, 
the infarct size was reduced and the neurological score improved by treatment with U0126 
(Henriksson et al., 2007;Maddahi and Edvinsson, 2008;Maddahi et al., 2009). Organ culture of rat 
middle cerebral artery gives a strong endothelin ETB receptor mediated contraction while U0126 
diminished this endothelin ETB receptor mediated contraction and the elevated endothelin ETB 
receptor mRNA level. The serotonin 5-HT1B receptor mediated contraction is upregulated by organ 
culture and depressed by U0126 at the protein level. 
 
 
5 Conclusion 
This present study has shown that the MEK/ERK1/2 pathway is involved in GPCRs alteration seen 
after 48 h of organ culture. Since similar receptor alterations are seen in cerebrovascular diseases in 
vivo, organ culture is a convenient way to studying mechanisms involved in GPCR alterations. The 
MEK1/2 specific inhibitor U0126 provides the most promising results; it has the ability to inhibit 
upregulation even when added 6 h after the initiation of organ culture. U0126 attenuated the 
upregulation of endothelin ETB, serotonin 5-HT1B, and thromboxane A2 receptors in a time de-
pendent manner, which may open a window of opportunity to modify in vivo situations where the 
MEK/ERK pathway has a central role.  
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(A) Endothelin ETA and ETB receptor mediated contraction
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(B) Endothelin ETA receptor mediated contraction
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(C) Endothelin ETB receptor mediated contraction
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Figure 3B
(B) Endothelin ETB receptor immunohistochemistry 
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Figure 4A
(A) Serotonin 5-HT1B receptor mediated contraction
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Figure 4B
(A) Serotonin 5-HT1B receptor immunohistochemistry
Fresh 48 h Vehicle 48 h U0126
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(A) Thromboxane A2 receptor mediated contraction
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Figure 5B
(B) Thromboxane A2 receptor immunohistochemistry
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Figure legends 
 
Figure 1 – Organ culture experiment time line 
Figure 2 - Contractile responses to the cumulative application of endothelin-1 (A), endothelin-1 
after preincubation with sarafotoxin 6c (B), or sarafotoxin 6c (C) to fresh or incubated middle 
cerebral arteries with vehicle or 10 µM U0126. Values given represent means ± s.e.m. n=6-16. P < 
0.05 = * and P = 0.001 = ***. 
 
Figure 3 – Endothelin ETB receptor mRNA level relative to elongation factor (EF-1) in fresh or 
incubated middle cerebral arteries with vehicle or 10 µM U0126 (A). Immunohistochemistry double 
staining against endothelin ETB receptor and β-actin of fresh or incubated middle cerebral arteries 
with vehicle or 10 µM U0126, only 488 nm green channel (endothelin ETB receptor staining) is 
shown, 60x magnification (B). Values given represent means ± s.e.m. n=7-8 for real time PCR and 
n=6 for immunohistochemistry. P < 0.05 = * and P = 0.01 = **. n.s. = not significant. 
 
Figure 4 - Contractile responses to the cumulative application of 5-carboxamidotryptamine to fresh 
or incubated middle cerebral arteries with vehicle or 10 µM U0126 (A). Immunohistochemistry 
double staining against serotonin 5-HT1B receptor and β-actin of fresh or incubated middle cerebral 
arteries with vehicle or 10 µM U0126, only 488 nm green channel (serotonin 5-HT1B receptor 
staining) is shown, 60x magnification (B). Values given represent means ± s.e.m. n=6-7 for 
myograph and n=4 for immunohistochemistry. P < 0.05 = * and P = 0.001 = ***. 
 
Figure 5 - Contractile responses to the cumulative application of U46619 to fresh or incubated 
middle cerebral arteries with vehicle or 10 µM U0126 (A). Immunohistochemistry double staining 
against thromboxane A2 receptor and β-actin of fresh or incubated middle cerebral arteries with 
vehicle or 10 µM U0126, only 488 nm green channel (thromboxane A2 receptor staining) is shown, 
60x magnification (B). Values given represent means ± s.e.m. n=7-11 for myograph experiments, 
n=7-8 for real time PCR, and n=6 for immunohistochemistry. P < 0.05 = *. n.s. = not significant. 
 
Figure 6 - Immunohistochemistry double staining against pERK1/2 and β-actin of fresh or 
incubated middle cerebral arteries with vehicle or 10 µM U0126, 10 µM PD98059, 10 µl SL327, or 
1 µM AG126, only 488 nm green channel (pERK 1/2 staining) is shown, 60x magnification. Values 
given represent means ± s.e.m. n=4 for immunohistochemistry. P < 0.05 = *. n.s. = not significant. 
 
Figure legends
Gene GenBank ID Forward primer Reverse primer 
ETA NM_012550 5'-ATTGCCCTCAGCGAACAC-3' 5'-CAACCAAGCAGAAGACGGTC-3' 
ETB  NM_017333 5'-GATACGACAACTTCCGCTCCA-3' 5'-GTCCACGATGAGGACAATGAG-3' 
5-HT1B NM_022225 5’-TCCGGGTCTCCTGTGTACGT-3’ 5’-GGCGTCTGAGACTCGCACTT-3’ 
TA2  NM_017054 5’-ATCTCCCATCTTGCCATAGTCC–3’ 5’-CGATGATCCTTGGAGCCTAAAG-3’ 
EF-1 NM_175838 5'-GCAAGCCCATGTGTGTTGAA-3'  
 
5'-TGATGACACCCACAGCAACTG-3' 
 
GAPDH NM_017008 5′-GGCCTTCCGTGTTCCTACC-3′ 5′-CGGCATGTCAGATCCACAAC-3′ 
 
Table 1 - Primer sequences of the respective genes analysed by real time PCR. ETA: endothelin 
ETA receptor; ETB: endothelin ETB receptor; 5-HT1B: serotonin 5-HT1B receptor; TP: 
thromboxane A2 receptor; EF-1: enlongation factor-1; and GAPDH: Glyceraldehyde 3-phosphate 
dehydrogenase. 
 
Table 1
   ET-1 ET-1 (S6c) S6c 5-CT  U46619 
Fresh Emax in % of K+ 139 ± 14 127  ± 16 5 ± 1 52 ± 14 
 
 137 ± 13 
 
pEC50 9.3 ± 0.1 9.4 ± 0.2 - 5.8 ± 0.1  
 
 7.0 ± 0.2 
48 h Vehicle Emax in % of K+ 140 ± 10 109 ± 10 121 ± 6 24 ± 11  
Emax(1) 
112 ± 11  
Emax(2) 
145 ± 4 
 
pEC50 10.8 ± 0.2 10.4 ± 0.2 10.7 ± 0.1 8.8 ± 1.3 
pEC50(1) 
6.5 ± 0.3  
pEC50(2) 
7.8 ± 0.1 
48 h 10 µM 
U0126 
Emax in % of K+ n.d. 124 ± 8 78 ± 8 n.d.  n.d. 
 
pEC50 n.d. 11.3 ± 0.2 9.9 ± 0.1 n.d. 
 
n.d. 
42 h 10 µM 
U0126 
Emax in % of K+ 145 ± 19 172 ± 26 10 ± 4 7 +/- 2  42 ± 10 
 
pEC50 9.8 ± 0.1 9.9 ± 0.1 - - 
 
6.4 ± 0.2 
36 h 10 µM 
U0126 
Emax in % of K+ 142 ± 9 196 ± 17 5 ± 1 5 ± 1  109 ± 18 
 
pEC50 9.6 ± 0.1 9.5 ± 0.1 - - 
 
6.6 ± 0.1 
24 h 10 µM 
U0126 
Emax in % of K+ 147 ± 12 154 ± 17  
 
70 ± 9 8 ± 2 
 
117 ± 18 
 
pEC50 10.0 ± 0.3 10.1 ± 0.2 10.4 ± 0.2 - 
 
6.9 ± 0.1 
 
 
Table 1 – Emax and pEC50 values of fresh or 48 h incubated MCA with vehicle or 10 µM U0126. 
Values given for all agonist experiments and as mean ± s.e.m. Emax(1), Emax(2), pEC50(1), and 
pEC50(2) values given for 48 h organ culture of MCA 5-CT biphasic sigmoid curve. n.d. = not 
determined. ET-1: endothelin-1; S6c: sarafotoxin 6c; 5-CT: 5-carboxamidotryptamine.  
 
 
Table 2
